Gilead Sciences Inc (GILD) Stock Price, Quote & News

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 574 3000

Fax: 650 578 9264

Website: www.gilead.com

Address:

333 Lakeside Drive, Foster City, United States

BiotechBonesaw Sep. 1 at 12:08 PM

$NVS $SLS $TNXP $ALT Feeling awful for patients in the UK. $GILD isn’t even submitting its new breast cancer drug in that country due to their outdated QALY projection (a healthy year of life is only worth $20K in London???). God bless America 🇺🇸 https://www.bbc.com/news/articles/c4gzk1p90q1o.amp

1 · Reply

Jblack500 Aug. 29 at 10:02 PM

$GILD added today. Buy zone for max gain

0 · Reply

Jblack500 Aug. 29 at 9:57 PM

$GILD $ABBV $BBIO gilead chart primed to climb next week

0 · Reply

Reanimated666 Aug. 29 at 2:36 PM

$GILD Oversold in uptrend Backed up the truck 🛻

1 · Reply

biolover Aug. 28 at 9:18 PM

$GILD $VKTX never thinking of Gilead. But they have oral SM GLP1 in phase 1 ( Pfizer scaffold ) that likely lower enthusiasm given Pfizer and Lilly stories. They never indicated a lot of budget for M&A but I imagine with this no need for biopsy change , they could rethink their position. Why they need to lay this much for mdgl weak drug ? They don’t need imminent cash. Although their management has not shown long term vision yet on anything.

1 · Reply

EmSol Aug. 28 at 8:50 PM

$VKTX another beautiful day and during this week, $GILD is going down and down, I told I will not be surprise if the bought something

1 · Reply

sister Aug. 28 at 5:33 PM

$MRNA every dip be bought back to $170.47 . . . Especially with Pfizer and JNJ reversing. $GILD $MRK

0 · Reply

DomLuminous Aug. 28 at 3:07 PM

$GILD odd this is going down after a clean breakout

1 · Reply

Dogtag Aug. 28 at 2:51 PM

$GILD Gilead Sciences that was an expensive nothing burger. $4.9 billion and probably a lot of millions getting magrolimab to Phase 3 just to fail and actually increased risk of death in patients 🤣 Meanwhile SELLAS Life Sciences Group, Inc. approved to begin trials in frontline AML after succeeding in their phase 2 by achieving more than double the target response rates 🤩 $SLS

0 · Reply

JDR1983 Aug. 28 at 2:50 PM

$GILD Buying.

0 · Reply

EU approves Gilead's new injection for preventing HIV

Aug 26, 2025, 3:00 AM EDT - 6 days ago

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

Aug 21, 2025, 10:21 AM EDT - 11 days ago

Gilead unit to acquire cell therapy developer Interius for $350 million

Aug 21, 2025, 8:54 AM EDT - 11 days ago

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS

Aug 21, 2025, 8:30 AM EDT - 11 days ago

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

Aug 20, 2025, 10:48 PM EDT - 11 days ago

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Aug 20, 2025, 4:41 PM EDT - 11 days ago

Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists

CVS

Aug 20, 2025, 4:05 PM EDT - 11 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

Aug 16, 2025, 8:15 AM EDT - 16 days ago

Our Top 10 High Growth Dividend Stocks - August 2025

APH AVGO BBVA BK EME FIX HWM

Aug 11, 2025, 6:25 PM EDT - 20 days ago

Final Trade: BSY, GDX, MNDY, GILD

GDX MNDY BSY

Aug 8, 2025, 3:36 PM EDT - 23 days ago

Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook

Aug 8, 2025, 10:55 AM EDT - 24 days ago

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Aug 8, 2025, 5:18 AM EDT - 24 days ago

These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences

EXPE PINS TTD TWLO

Aug 7, 2025, 9:39 PM EDT - 24 days ago

Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:26 PM EDT - 24 days ago

Gilead Sciences Q2: The New Drug That Could Change Everything

Aug 7, 2025, 4:25 PM EDT - 24 days ago

Gilead posts flat quarterly profit, raises full-year outlook

Aug 7, 2025, 4:02 PM EDT - 24 days ago

Gilead Sciences Announces Second Quarter 2025 Financial Results

Aug 7, 2025, 2:51 PM EDT - 24 days ago

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Aug 1, 2025, 12:01 PM EDT - 4 weeks ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GSK JNJ LLY

Aug 1, 2025, 8:31 AM EDT - 4 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 4 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 3:35 PM EDT - 4 weeks ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GSK JNJ LLY

Jul 31, 2025, 3:00 PM EDT - 4 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GSK JNJ LLY

Jul 31, 2025, 2:28 PM EDT - 4 weeks ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GSK JNJ LLY

Jul 31, 2025, 2:19 PM EDT - 4 weeks ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV LLY PFE AMGN AZN BMY GSK

Jul 31, 2025, 1:48 PM EDT - 4 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GSK JNJ LLY

Jul 25, 2025, 1:25 PM EDT - 5 weeks ago

Final Trades: Gilead, Blackstone, Disney and Visa

BX DIS V

Jul 25, 2025, 1:18 PM EDT - 5 weeks ago

Calls of the Day: Gilead, Chipotle and P&G

CMG PG

Jul 25, 2025, 12:12 PM EDT - 5 weeks ago

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

Jul 25, 2025, 3:03 AM EDT - 5 weeks ago

EU regulator backs Gilead's twice-yearly injection for HIV prevention

Jul 25, 2025, 3:00 AM EDT - 5 weeks ago

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

Jul 24, 2025, 4:05 PM EDT - 5 weeks ago

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 19, 2025, 8:00 AM EDT - 6 weeks ago

Our Top 10 High Growth Dividend Stocks - July 2025

APH AVGO BBVA BK CARR EME FIX

Jul 17, 2025, 11:06 AM EDT - 6 weeks ago

Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player

Jul 16, 2025, 3:08 PM EDT - 6 weeks ago

Why Merck Is A Better Dividend Stock Than Gilead Sciences

MRK

Jul 16, 2025, 3:12 AM EDT - 6 weeks ago

GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm

Jul 14, 2025, 2:48 PM EDT - 6 weeks ago

WHO recommends Gilead's twice-yearly injection for HIV prevention

Jul 14, 2025, 9:30 AM EDT - 7 weeks ago

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Jul 9, 2025, 4:37 PM EDT - 7 weeks ago

AHF: Gilead's Greed Costs Latin America HIV Protection

Jul 9, 2025, 12:40 PM EDT - 7 weeks ago

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Jul 9, 2025, 8:16 AM EDT - 7 weeks ago

Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries

Jul 9, 2025, 8:00 AM EDT - 7 weeks ago

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Jul 8, 2025, 1:23 PM EDT - 7 weeks ago

Final Trades: Synovus, Nextera Energy, Gilead and the IYF

IYF NEE SNV

Jul 8, 2025, 10:41 AM EDT - 7 weeks ago

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

BMY JNJ NVO PFE VRTX

Jul 7, 2025, 6:29 PM EDT - 7 weeks ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO BMRN INSM XBI

Jun 27, 2025, 10:59 AM EDT - 2 months ago

Gilead shares rise after US top court ruling on preventative coverage

Jun 25, 2025, 9:15 AM EDT - 2 months ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

KYMR

Jun 25, 2025, 7:00 AM EDT - 2 months ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

KYMR

BiotechBonesaw Sep. 1 at 12:08 PM

1 · Reply

Jblack500 Aug. 29 at 10:02 PM

$GILD added today. Buy zone for max gain

0 · Reply

Jblack500 Aug. 29 at 9:57 PM

$GILD $ABBV $BBIO gilead chart primed to climb next week

0 · Reply

Reanimated666 Aug. 29 at 2:36 PM

$GILD Oversold in uptrend Backed up the truck 🛻

1 · Reply

biolover Aug. 28 at 9:18 PM

1 · Reply

EmSol Aug. 28 at 8:50 PM

$VKTX another beautiful day and during this week, $GILD is going down and down, I told I will not be surprise if the bought something

1 · Reply

sister Aug. 28 at 5:33 PM

$MRNA every dip be bought back to $170.47 . . . Especially with Pfizer and JNJ reversing. $GILD $MRK

0 · Reply

DomLuminous Aug. 28 at 3:07 PM

$GILD odd this is going down after a clean breakout

1 · Reply

Dogtag Aug. 28 at 2:51 PM

0 · Reply

JDR1983 Aug. 28 at 2:50 PM

$GILD Buying.

0 · Reply

JFDI Aug. 28 at 12:39 PM

$GILD

0 · Reply

RanchElsie Aug. 27 at 1:25 PM

$BTAI Lotta folks thought they were going to be dancing down the yellow brick road this weekend. $BTAI needs a Pharma partner &amp; investor to produce this promising treatment. They’ll keep doing these calls/PRs to keep up interest. They’ll have to. If you’re in it for the long haul, then righteous. If you thought you were going be buying the drinks in crowded tonight, or even this weekend, I hope you have some extra coin. Gonna be awhile. $GILD had same journey with hepatitis drug.

0 · Reply

RanchElsie Aug. 27 at 1:22 PM

$NIO Lotta folks thought they were going to be dancing down the yellow brick road this weekend. $BTAI needs a Pharma partner & investor to produce this promising treatment. They’ll keep doing these calls/PRs to keep up interest. They’ll have to. If you’re in it for the long haul, then righteous. If you thought you were going be buying the drinks in crowded tonight, or even this weekend, I hope you have some extra coin. Gonna be awhile. $GILD had same journey with hepatitis drug.

0 · Reply

EmSol Aug. 27 at 11:07 AM

$GILD yep $110 stop make sense it’s a dangerous zone

0 · Reply

EmSol Aug. 27 at 11:06 AM

$ABBV $GILD Gilead look like a M ready to be written. Stop at $110 make sense

1 · Reply

RiskForge Aug. 27 at 6:28 AM

$GILD losing steam after a push, watching for retracement.

1 · Reply

Jblack500 Aug. 26 at 8:36 PM

$GILD $ABBV a clean break for gild will be meaningful with this beast of a chart

0 · Reply

Jblack500 Aug. 26 at 8:15 PM

$GILD $BBIO nice closes for these two. I think gild is ready to make the turn towards new all time highs after this recent pullback. Chart looks solid after some of the gains were digested off the move to 120.

0 · Reply

scientificway Aug. 26 at 7:02 PM

$GILD ready to move up, XTNT showing a strong support here and most likely going up from here.

0 · Reply

EmSol Aug. 26 at 5:54 PM

$GILD just beautiful

1 · Reply

Jblack500 Aug. 26 at 4:35 PM

$GILD $ABBV $SMMT $EXEL $BBIO Bought more gild 114.40. Took advantage of recent pullback. I see it bouncing off this 114 area. Raised my cost basis to 84 dollars....GL

0 · Reply

FatMoneyScience Aug. 26 at 3:15 PM

$ALT Sound familiar? Company sold to $GILD 23 days later.

2 · Reply

Market Cap	140.17B
Revenue (ttm)	28.75B
Net Income (ttm)	480.00M
EPS (ttm)	N/A
PE Ratio	14.60
Forward PE	13.90
Profit Margin	1.67%
Debt to Equity Ratio	1.27

Volume	4,630,500
Avg Vol	6,649,194
Day's Range	N/A - N/A
Shares Out	1.24B
Stochastic %K	9%
Beta	0.36
Analysts	Strong Sell
Price Target	$126.33